Clinical trials: Lamivudine
HIV Infections
A Comparison of Two Anti-HIV Triple-Drug Combinations in HIV-Infected Patients
The purpose of this study is to compare the safety and effectiveness of two anti-HIV drug combinations when given to HIV-infected patients who have never been treated with anti-HIV drugs.
- Trial name
- NCT00002168
- Testing
- Indinavir sulfate, Lamivudine, Stavudine
- Where
- 13 sites in United States, Puerto Rico
- Volunteers
- 200 people
- Sponsor
- Bristol-Myers Squibb
HIV Infections
Tenofovir DF + Efavirenz (TDF+EFV) Versus Tenofovir DF + Efavirenz + Lamivudine (TDF+EFV+3TC) Maintenance Regimen in Virologically Controlled Patients: COOL Trial
Primary objective: Evaluation of the efficacy of TDF+3TC+EFV versus TDF+EFV QD to maintain plasma HIV-1 RNA BLQ (< 50 copies/mL) (c/mL) at 48 weeks (W48) Main Secondary objectives: Comparison of the two arms for genotypic…
- Trial name
- COOL (NCT00643968)
- Testing
- EFV+TDF, EFV+3TC+TDF
- Where
- France
- Volunteers
- 140 people
- Sponsor
- Gilead Sciences
Chronic Hepatitis B
Lamivudine Plus Interferon Versus Lamivudine For The Treatment Of HBeAg Positive Chronic Hepatitis B Virus (HBV)
This is a single-centre prospective randomised study comparing the virological and histological response of HBV infection to lamivudine in combination with interferon versus lamivudine alone.
- Trial name
- NCT00140725
- Testing
- Lamivudine plus Polyethylene glyco-interferon alfa-2b, Lamivudine
- Where
- Hong Kong
- Volunteers
- 160 people
- Sponsor
- GlaxoSmithKline
HIV Infections, Lipodystrophy
A Study of Increased Lactic Acid and Abnormal Fat Distribution in HIV-Positive Patients
The purpose of this study is to see if the findings of increased lactic acid and abnormal fat distribution get better when d4T is replaced with abacavir, abacavir plus lamivudine, or Combivir (a pill containing lamivudine plus…
- Trial name
- NCT00005764
- Testing
- Lamivudine/Zidovudine, Abacavir sulfate, Lamivudine
- Where
- 31 sites in United States
- Volunteers
- 100 people
- Sponsor
- Glaxo Wellcome
Hepatitis B, Chronic
A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With Lamivudine Resistant HBeAg-Negative Chronic Hepatitis B.
This single arm study will evaluate the efficacy and safety of PEGASYS in patients with lamivudine resistant HBeAg negative chronic hepatitis B. Patients will receive PEGASYS 180 micrograms s.c.
- Trial name
- NCT00460850
- Testing
- peginterferon alfa-2a (40KD) [PEGASYS]
- Where
- 4 sites in Turkey (Türkiye)
- Volunteers
- 60 people
- Sponsor
- Hoffmann-La Roche
HIV
Combivir And Maraviroc In Antiretroviral Naive Subjects In Russia
One hundred subjects in Russia will be treated with a combination of Combivir (zidovudine and lamivudine) and maraviroc as their first line HIV therapy.
- Trial name
- NCT01275625
- Testing
- HIV therapy
- Where
- 8 sites in Russia
- Volunteers
- 98 people
- Sponsor
- ViiV Healthcare
Infection, Human Immunodeficiency Virus
An Expanded Access Protocol for Subjects Who Have Completed Clinical Studies Involving Maraviroc
This is an open-label protocol designed to provide continued access to maraviroc to only those subjects who have completed previous studies of maraviroc and continue to receive clinical benefit.
- Trial name
- NCT01776996
- Testing
- Continued Access Arm
- Where
- 28 sites in Argentina, Belgium and 5 more
- Sponsor
- ViiV Healthcare
HIV Infections
Safety and Antiviral Study of ACH-126, 443 (Beta-L-Fd4C) in the Treatment of Adults With HIV Infection and Modestly Detectable Viral Load.
To determine safety and efficacy of ACH-126,443 on the treatment of adults with HIV infection who have modestly detectable viral load while on stable triple combination antiretroviral therapy including 3TC.
- Trial name
- NCT00040157
- Testing
- ACH126-443 (Beta-L-Fd4C)
- Where
- 13 sites in United States
- Volunteers
- 60 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
HIV Infection
Abacavir/Lamivudine Versus Emtricitabine/Tenofovir Both In Combination With Lopinavir/Ritonavir For The Treatment Of HIV
This study was designed to test the safety and effectiveness of EPZICOM(abacavir/lamivudine) and TRUVADA (emtricitabine/tenofovir) for the treatment of HIV infection when both are used in combination with KALETRA…
- Trial name
- HEAT (NCT00244712)
- Testing
- emtricitabine/tenofovir, abacavir/lamivudine
- Where
- 74 sites in United States, Puerto Rico
- Volunteers
- 688 people
- Sponsor
- GlaxoSmithKline
HIV Infections
AVX754 (a New Nucleoside Reverse Transcriptase Inhibitor [NRTI]) to Treat Drug-resistant HIV
The study will measure how safe and effective AVX754 (a new drug for the treatment of HIV) is in treating HIV-1 infected people who have failed treatment with lamivudine.
- Trial name
- NCT00126880
- Testing
- AVX754, 3TC
- Where
- Australia
- Volunteers
- 52 people
- Sponsor
- Avexa
Infection, Human Immunodeficiency Virus
Evaluation of the Bioequivalence of a Combined Formulated Tablet
Dolutegravir (DTG, GSK1349572) is a next-generation integrase inhibitor (INI) currently in phase 3 clinical trials for human immunodeficiency virus (HIV).
- Trial name
- NCT01622790
- Testing
- Dolutegravir 50 mg/abacavir 600 mg/lamivudine 300 mg, Dolutegravir 50 mg, abacavir 600 mg/lamivudine 300 mg
- Where
- United States
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
HIV Infections
A Study of Combivir Plus Abacavir Plus 141W94 in Patients Who Previously Have Used Anti-HIV Drugs
The purpose of this study is to test the effectiveness of Combivir plus abacavir plus 141W94 in patients who previously have used anti-HIV drugs.
- Trial name
- NCT00002217
- Testing
- Lamivudine/Zidovudine, Abacavir sulfate, Amprenavir
- Where
- United States
- Sponsor
- Glaxo Wellcome
HIV, HIV Infection
Clinical Trial to Evaluate the Efficacy and Safety of Codivir® in Addition to Standard Antiretroviral Treatment for HIV Infection in Antiretroviral-naïve Participants
The study will begin with a two-week lead-in period (W-2 and W-1), when participants randomized to Codivir® will receive Codivir® 2 mL, 1 subcutaneous injection every day.
- Trial name
- Codivir® (NCT06676410)
- Testing
- ICF, Eligibility Assessment, Demographic data
- Where
- Brazil
- Volunteers
- 40 people
- Sponsor
- Code Pharma
HIV Infections
ABT-378/Ritonavir in Combination With Reverse Transcriptase Inhibitors in Antiretroviral Naïve HIV-Infected Subjects
To assess the safety, tolerability and antiviral activity of lopinavir/ritonavir when administered orally in antiretroviral-HIV-1 infected subjects.
- Trial name
- NCT00004578
- Testing
- Lopinavir/Ritonavir, Lamivudine, Stavudine
- Where
- 10 sites in United States
- Volunteers
- 100 people
- Sponsor
- Abbott
Infection, Human Immunodeficiency Virus I
A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial)
The purpose of this trial is to assess the non-inferior antiviral activity of GSK1349572 50 mg plus Abacavir/Lamivudine once daily versus Efavirenz/Emtricitabine/Tenofovir disoproxil fumarate (ATRIPLA® a trade mark of…
- Trial name
- NCT01263015
- Testing
- Dolutegravir, Atripla, Abacavir/Lamivudine
- Where
- 145 sites in United States, Australia and 10 more
- Volunteers
- 844 people
- Sponsor
- ViiV Healthcare
HIV Infections, Acquired Immunodeficiency Syndrome
A Study to Evaluate the Safety and Efficacy of an Investigational Drug in HIV Infected Patients (0518-004)(COMPLETED)
This is a study that will investigate the safety and efficacy of an investigational drug in Human immunodeficiency virus (HIV) infected patients.
- Trial name
- NCT00100048
- Testing
- Comparator: MK0518 monotherapy, Comparator: MK0518 combination therapy, Comparator: efavirenz
- Volunteers
- 206 people
- Sponsor
- Merck Sharp & Dohme LLC
HIV Infections
Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants
The First Long-Acting Injectable Regimen (FLAIR) study is being conducted to establish if human immunodeficiency virus type-1 (HIV-1) infected adult participants whose virus is virologically suppressed on an integrase inhibitor…
- Trial name
- NCT02938520
- Testing
- Cabotegravir (CAB) tablet, Rilpivirine (RPV) tablet, Cabotegravir - Injectable Suspension (CAB LA)
- Where
- 108 sites in United States, Canada and 9 more
- Volunteers
- 631 people
- Sponsor
- ViiV Healthcare
Human Immunodeficiency Virus (HIV)
Human Immunodeficiency Virus (HIV) Postexposure Prophylaxis (PEP) With Darunavir/Ritonavir (DRV/r)
The primary purpose of this study is to assess the rate of early discontinuation from randomized Human Immunodeficiency Virus (HIV) Postexposure Prophylaxis (PEP) for any reason other than confirmation of the negative HIV…
- Trial name
- PEPDar (NCT01516970)
- Testing
- Darunavir/Ritonavir (DRV/r), Lopinavir in fixed combination with Ritonavir, Zidovudine
- Where
- 17 sites in Germany
- Volunteers
- 312 people
- Sponsor
- Janssen-Cilag G.m.b.H
Hepatitis B
Tenofovir Disoproxil Fumarate (Tenofovir DF) Versus Emtricitabine/Tenofovir DF in Subjects Resistant to Lamivudine
The aim of therapy for the treatment of chronic hepatitis B virus (HBV) is to maintain suppression of viral replication to prevent the emergence of complications, which requires long-term therapy.
- Trial name
- NCT00737568
- Testing
- TDF, FTC/TDF
- Where
- 69 sites in United States, Austria and 12 more
- Volunteers
- 280 people
- Sponsor
- Gilead Sciences
HIV Infections
A Comparison of Three Anti-HIV Drug Combinations Containing Saquinavir Soft Gelatin Capsules Used in HIV-1 Infected Patients
To determine the proportion of patients whose plasma HIV-1 RNA level falls below the level of detection (< 400 copies/ml) at week 24 of study therapy.
- Trial name
- NCT00002378
- Testing
- Ritonavir, Nelfinavir mesylate, Saquinavir
- Where
- 102 sites in United States, Germany and 4 more
- Volunteers
- 825 people
- Sponsor
- Hoffmann-La Roche